Moderna announced on Monday that it is lowering its sales expectations for 2025 by $1 billion due to a slowdown in the adoption of the respiratory syncytial virus (RSV) vaccine and weak demand for COVID-19 vaccines.
The company clarified that its annual revenue estimates for 2025 range from $1.5 billion to $2.5 billion, with the expectation that most of this revenue will come in the second half of the year. These expectations are significantly lower than previous estimates, which ranged from $2.5 billion to $3.5 billion, and also lower than market estimates of $2.95 billion.
In its efforts to boost growth, Moderna is betting on new innovations, having submitted a request to the U.S. Food and Drug Administration for approval of a combined vaccine for protection against COVID-19 and influenza. A regulatory decision regarding this request is expected by May 2025.
Moderna also expects to announce preliminary results on the seasonal influenza vaccine later this year, assuming sufficient cases are available in the first season. If the data is not complete, the study will be extended into the second season.
In stock performance, Moderna shares (NASDAQ: MRNA) recorded a sharp decline of 24.93%, with a drop of $10.11 per share, trading at levels of $32.14 during American stock market transactions.
